MSI (Microsatellite instability)

P2, N=2, Active, not recruiting, National Cancer Institute (NCI) | N=240 --> 2 | Trial completion date: Oct 2027 --> Jun 2027 | Trial primary completion date: Oct 2027 --> Jan 2026

Future directions include prospective multicenter validation in clinical workflows, standardization of evaluation frameworks, and implementation of uncertainty estimation to support clinical decision-making. Overall, AI-enabled digital pathology represents a promising approach for advancing precision oncology in GC by improving biomarker assessment and providing insights into tumor biology.

NT5E accelerates disease progression by promoting malignant biological behaviors in colorectal cancer and synergistically shaping an immunosuppressive microenvironment with PD-L1. Its overexpression constitutes an independent adverse prognostic factor. This discovery offers novel insights for anti-PD-1/PD-L1 combination immunotherapy.

IL-17-responsive, tumor cell-intrinsic inflammatory programming remodels the tumor immune microenvironment toward an immunotherapy-permissive state. These findings establish IL-17-responsive tumor cell inflammatory programming as a mechanistic axis shaping immune checkpoint sensitivity and provide a rationale for biomarker-guided immunotherapy strategies.

We also discuss how MEG alterations contribute to the Warburg effect, chemoresistance, and tumor metastasis, which are critical barriers to effective cancer treatment. This synthesis highlights the pivotal role of mitochondrial genetics in cancer biology and positions MEGs as promising targets for innovative anticancer therapies.

Liver lesions shrank after treatment with octreotide and Lutetium-177 vipivotide tetraxetan...The role of microsatellite instability (MSI) as a screening marker, and personalized treatment approaches like immunotherapy for dMMR tumors. Understanding these correlations may assist in early discovery, surveillance, and customized treatment for patients dealing with LS-associated malignancies.

In patients with dMMR or MSI-H locally advanced colorectal cancer, neoadjuvant toripalimab plus celecoxib significantly increased the proportion of patients attaining pathological complete response compared with toripalimab monotherapy, with a similar safety profile. These findings support further investigation of this combination strategy in larger phase 3 trials.

P1/2, N=482, Recruiting, BioNTech SE | Trial completion date: May 2031 --> Dec 2032

CC was associated with poor colorectal cancer outcomes in our study. Therefore, we believe that it is important to identify and quantify cannibal cells during routine histopathology examinations to demonstrate their morphological predictive value.

P=N/A, N=60, Recruiting, Geneplus-Beijing Co. Ltd. | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

pylori in the stomach, F. nucleatum in the colon) shape the prevalence of each archetype. By elucidating the molecular circuits and environmental dependencies underlying these spatially encoded resistance programs, we articulate a translational imperative: archetype-guided spatial biomarkers and targeted microenvironment-remodeling strategies provide the most viable framework to extend durable immunotherapeutic benefit to the historically refractory MSS/pMMR gastrointestinal cancer population.